{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T04:15:51Z","timestamp":1727151351647},"reference-count":27,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2022,6,30]]},"DOI":"10.5582\/ddt.2022.01032","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T22:09:26Z","timestamp":1651788566000},"page":"139-141","source":"Crossref","is-referenced-by-count":3,"title":["Oral high-dose acetylcysteine: Effective against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)?"],"prefix":"10.5582","volume":"16","author":[{"given":"Guangbin","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Third People's Hospital of Shenzhen, Shenzhen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhou","family":"Lu","sequence":"additional","affiliation":[{"name":"National Center for Infectious Disease Research, The Third People's Hospital of Shenzhen, Shenzhen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Vitiello A, Ferrara F, Auti AM, Di Domenico M, Boccellino M. Advances in the Omicron variant development. J Intern Med. 2022. doi: 10.1111\/joim.13478","DOI":"10.1111\/joim.13478"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Micheli V, Bracchitta F, Rizzo A, Mancon A, Mileto D, Lombardi A, Stefanelli P, Gismondo MR. First identification of the new SARS-CoV-2 Omicron variant (B.1.1.529) in Italy. Clin Infect Dis. 2022. doi: 10.1093\/cid\/ciab1044","DOI":"10.1093\/cid\/ciab1044"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J. 2020; 34:13185-13193.","DOI":"10.1096\/fj.202001807"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Schwalfenberg GK. N-acetylcysteine: A review of clinical usefulness (an old drug with new tricks). J Nutr Metab. 2021; 2021:9949453.","DOI":"10.1155\/2021\/9949453"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol. 2011; 82:548-555.","DOI":"10.1016\/j.bcp.2011.05.014"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl J Jr. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol. 2010; 79:413-420.","DOI":"10.1016\/j.bcp.2009.08.025"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Demedts M, Behr J, Buhl R, <i>et al<\/i>. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353:2229-2242.","DOI":"10.1056\/NEJMoa042976"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Menicagli R, Limodio M, Limodio M, Casotti MT, Menicagli L. Pulmonary Covid fibrosis a new pharmaceutic approach. Int J Prev Med. 2021; 12:35.","DOI":"10.4103\/ijpvm.IJPVM_462_20"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kumar P, Osahon O, Vides DB, Hanania N, Minard CG, Sekhar RV. Severe glutathione deficiency, oxidative stress and oxidant damage in adults hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-acetylcysteine) supplementation. Antioxidants (Basel). 2021; 11:50.","DOI":"10.3390\/antiox11010050"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Jorge-Aar\u00f3n RM, Rosa-Ester MP. N-acetylcysteine as a potential treatment for COVID-19. Future Microbiol. 2020; 15:959-962.","DOI":"10.2217\/fmb-2020-0074"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Poe FL, Corn J. N-acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Med Hypotheses. 2020; 143:109862.","DOI":"10.1016\/j.mehy.2020.109862"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wong KK, Lee SWH, Kua KP. N-acetylcysteine as adjuvant therapy for COVID-19 - A perspective on the current state of the evidence. J Inflamm Res. 2021; 14:2993-3013.","DOI":"10.2147\/JIR.S306849"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Elhidsi M, Fachrucha F, Irawan RY. N-acetylcysteine for COVID-19: A potential adjuvant therapy. J Health Sci. 2021; 11:1-6.","DOI":"10.17532\/jhsci.2020.1156"},{"key":"14","unstructured":"14. Mohanty RR, Padhy BM, Das S, Meher BR. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: Review of current evidence. Eur Rev Med Pharmacol Sci. 2021; 25:2802-2807."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Downs JW, Cumpston KL, Kershner EK, Troendle MM, Rose SR, Wills BK. Clinical outcome of massive acetaminophen overdose treated with standard-dose N-acetylcysteine. Clin Toxicol (Phila). 2021; 59:932-936.","DOI":"10.1080\/15563650.2021.1887493"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. De Backer J, Vos W, Van Holsbeke C, Vinchurkar S, Claes R, Parizel PM, De Backer W. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. Int J Chron Obstruct Pulmon Dis. 2013; 8:569-579.","DOI":"10.2147\/COPD.S49307"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Shen Y, Cai W, Lei S, Zhang Z. Effect of high\/low dose N-acetylcysteine on chronic obstructive pulmonary disease: A systematic review and meta-analysis. COPD. 2014; 11:351-358.","DOI":"10.3109\/15412555.2013.858315"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an <i>ex vivo<\/i> model of COPD exacerbation. Respir Res. 2017; 18:26.","DOI":"10.1186\/s12931-016-0500-y"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lai Z, Hanczko R, Bonilla E, <i>et al<\/i>. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial. Arthritis Rheumatology. 2012; 64:2937-2946.","DOI":"10.1002\/art.34502"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ozdemir ZC, Koc A, Aycicek A, Kocyigit A. N-acetylcysteine supplementation reduces oxidative stress and DNA damage in children with \u03b2-thalassemia. Hemoglobin. 2014; 38:359-364.","DOI":"10.3109\/03630269.2014.951890"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Doyon S, Klein-Schwartz W. Hepatotoxicity despite early administration of intravenous N-acetylcysteine for acute acetaminophen overdose. Acad Emerg Med. 2009; 16:34-39.","DOI":"10.1111\/j.1553-2712.2008.00296.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Pauley KA, Sandritter TL, Lowry JA, Algren DA. Evaluation of an alternative intravenous N-acetylcysteine regimen in pediatric patients. J Pediatr Pharmacol Ther. 2015; 20:178-185.","DOI":"10.5863\/1551-6776-20.3.178"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kanter MZ. Comparison of oral and <i>i.v.<\/i> acetylcysteine in the treatment of acetaminophen poisoning. Am J Health Syst Pharm. 2006; 63:1821-1827.","DOI":"10.2146\/ajhp060050"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tsai CL, Chang WT, Weng TI, Fang CC, Walson PD. A patient-tailored N-acetylcysteine protocol for acute acetaminophen intoxication. Clin Ther. 2005; 27:336-341.","DOI":"10.1016\/j.clinthera.2005.03.002"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Green JL, Heard KJ, Reynolds KM, Albert D. Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: A systematic review and meta-analysis. West J Emerg Med. 2013; 14:218-226.","DOI":"10.5811\/westjem.2012.4.6885"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Shi Z, Puyo CA. N-acetylcysteine to combat COVID-19: An evidence review. Ther Clin Risk Manag. 2020; 16:1047-1055.","DOI":"10.2147\/TCRM.S273700"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Amini A, Masoumi-Moghaddam S, Morris DL. Utility of bromelain and N-acetylcysteine in treatment of peritoneal dissemination of gastrointestinal mucin-producing malignancies. Anticancer Res. 2016; 36:3224-3225.","DOI":"10.1007\/978-3-319-28570-2"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/3\/16_2022.01032\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T22:14:50Z","timestamp":1727129690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/3\/16_2022.01032\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2022.01032","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"type":"print","value":"1881-7831"},{"type":"electronic","value":"1881-784X"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"article-number":"2022.01032"}}